Prolactinomas and pregnancy

Clinical Endocrinology

Volumn 73, Issue 2, 2010, Pages 147-148

  Molitch, Mark E ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; QUINAGOLIDE;

CONGENITAL MALFORMATION; DRUG EFFICACY; DRUG SAFETY; EXPERIENCE; FETUS DEVELOPMENT; HUMAN; HYPERPROLACTINEMIA; MULTIPLE PREGNANCY; NOTE; PREGNANCY; PREMATURE LABOR; PRIORITY JOURNAL; PROLACTINOMA; SPONTANEOUS ABORTION; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT;

AMINOQUINOLINES; ANTINEOPLASTIC AGENTS; DOPAMINE AGONISTS; EMBRYONIC DEVELOPMENT; ERGOLINES; FEMALE; HUMANS; PITUITARY NEOPLASMS; PREGNANCY; PREGNANCY COMPLICATIONS, NEOPLASTIC; PREGNANCY OUTCOME; PROLACTINOMA;

EID: 77954874815     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2010.03823.x     Document Type: Note

References (19)

1. Lebbe, M., Hubinont, C., Bernard, P. et al. (2010) Outcome of 100 pregnancies initiated under treatment with cabergoline in hyperprolactinaemic women. Clinical Endocrinology, 73, 230 236.
2. Krupp, P. Monka, C. (1987) Bromocriptine in pregnancy: safety aspects. Klinische Wochenschrift, 65, 823 827.
3. Krupp, P., Monka, C. Richter, K. (1988) The safety aspects of infertility treatments. Program of the Second World Congress of Gynecology and Obstetrics, Rio de Janeiro, October, 1988.
4. Canfield, M.A., Honein, M.A., Yuskiv, N. et al. (2006) National estimates and raceethnic-specific variation of selected birth defects in the United States, 1999-2001. Birth Defects Research. Part A, Clinical and Molecular Teratology, 76, 747 756.
5. Martin, J.A., Kung, H.-C., Mathews, T.J. et al. (2008) Annual summary of vital statistics: 2006. Pediatrics, 121, 788 801.
6. Webster, J., Piscitelli, G., Polli, A. et al. (1994) A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. New England Journal of Medicine, 331, 904 909.
7. Ferrari, C., Paracchi, A., Mattei, A.M. et al. (1992) Cabergoline in the long-term therapy of hyperprolactinemic disorders. Acta Endocrinologica, 126, 489 494.
8. Robert, E., Musatti, L., Piscitelli, G. et al. (1996) Pregnancy outcome after treatment with the ergot derivative, cabergoline. Reproductive Toxicology, 10, 333 337.
9. Ciccarelli, E., Grottoli, S., Razzzore, P. et al. (1997) Long-term treatment with cabergoline, a new long-lasting ergoline derivative, in idiopathic or tumorous hyperprolactinaemia and outcome of drug-induced pregnancy. Journal of Endocrinological Investigation, 20, 547 551.
10. Cannavò, S., Curtò, L., Squadrito, S. et al. (1999) Cabegoline: a first-choice treatment in patients with previously untreatd prolactin-secreting pituitary adenoma. Journal of Endocrinological Investigation, 22, 354 359.
11. Verhelst, J., Abs, R., Maiter, D. et al. (1999) Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. Journal of Clinical Endocrinology and Metabolism, 84, 2518 2522.
12. Ricci, E., Parazzini, F., Motta, T. et al. (2002) Pregnancy outcome after cabergoline treatment in early weeks of gestation. Reproductive Toxicology, 16, 791 793.
13. Bronstein, M.D. (2005) Prolactinomas and pregnancy. Pituitary, 8, 31 38.
14. Colao, A., Abs, R., Bárcena, D.G. et al. (2008) Pregnancy outcomes following cabergoline treatment: extended results from a 12-year observational study. Clinical Endocrinology, 68, 66 71.
15. Ono, M., Miki, N., Amano, K. et al. (2010) Individualized high-dose cabergoline therapy for hyperprolactinemic infertility in women with micro- and macroprolactinomas. Journal of Clinical Endocrinology and Metabolism, 95, 2672 2679.
16. Raymond, J.P., Goldstein, E., Konopka, P. et al. (1985) Follow-up of children born of bromocriptine-treated mothers. Hormone Research, 22, 239 246.
17. Webster, J. (1996) A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation. Drug Safety, 14, 228 238.
18. Molitch, M.E. (2006) Pituitary disorders during pregnancy. Endocrinology and Metabolism Clinics of North America, 35, 99 116.
19. Cohen-Kerem, R., Railton, C., Orfen, D. et al. (2005) Pregnancy outcome following non-obstetric surgical intervention. American Journal of Surgery, 190, 467 473.